The impact of the SARS-CoV-2 pandemic on umbilical cord blood transplantation in Japan: insights from an interrupted time series analysis.

IF 4.5 2区医学 Q1 HEMATOLOGY

Bone Marrow Transplantation Pub Date : 2025-04-17 DOI:10.1038/s41409-025-02588-0

Nobuhiko Nakamura, Tetsuji Morishita, Hiromi Hayashi, Motohito Okabe, Hideki Nakasone, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Satoshi Yoshihara, Masatsugu Tanaka, Tetsuya Nishida, Yuta Hasegawa, Ken-Ichi Matsuoka, Masashi Sawa, Tetsuya Eto, Makoto Onizuka, Yuta Katayama, Koji Kato, Fumihiko Ishimaru, Ken Tabuchi, Yoshiko Atsuta, Nobuhiro Kanemura, Takanori Teshima

{"title":"The impact of the SARS-CoV-2 pandemic on umbilical cord blood transplantation in Japan: insights from an interrupted time series analysis.","authors":"Nobuhiko Nakamura, Tetsuji Morishita, Hiromi Hayashi, Motohito Okabe, Hideki Nakasone, Naoyuki Uchida, Noriko Doki, Takahiro Fukuda, Satoshi Yoshihara, Masatsugu Tanaka, Tetsuya Nishida, Yuta Hasegawa, Ken-Ichi Matsuoka, Masashi Sawa, Tetsuya Eto, Makoto Onizuka, Yuta Katayama, Koji Kato, Fumihiko Ishimaru, Ken Tabuchi, Yoshiko Atsuta, Nobuhiro Kanemura, Takanori Teshima","doi":"10.1038/s41409-025-02588-0","DOIUrl":null,"url":null,"abstract":"<p><p>The SARS-CoV-2 pandemic disrupted healthcare systems worldwide, particularly affecting hematopoietic stem cell transplantation (HSCT) activities. Understanding the impact of the SARS-CoV-2 pandemic on transplant practices, especially in Japan, where cord blood transplantation (CBT) is prevalent, is crucial. A total of 40,444 allogeneic HSCT cases in Japan between 2011 and 2021 were examined using an interrupted time series analysis to assess the impact of COVID-19 on CBT utilization. Following the SARS-CoV-2 pandemic, CBT cases demonstrated a significant increase (11.06 [95% confidence interval (CI): 1.87 to 20.25] cases per month), whereas bone marrow transplantation cases decreased, by 10.74 cases per month (95% CI, -19.84 to -1.63 cases per month). Total HSCT cases remained stable with a level change of 5.47 cases per month (95% CI, -10.07 to 21.01 cases per month) and a trend change of -1.11 cases per month (95% CI, -2.22 to 0.004 cases per month). The interrupted time series analysis showed significantly increased CBT cases in Japan, highlighting its crucial role as an alternative transplant source during the pandemic. CBT offset the impact of the decrease in bone marrow transplantation and contributed to the maintenance of HSCT activity in Japan during the unprecedented crisis.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Marrow Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41409-025-02588-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The SARS-CoV-2 pandemic disrupted healthcare systems worldwide, particularly affecting hematopoietic stem cell transplantation (HSCT) activities. Understanding the impact of the SARS-CoV-2 pandemic on transplant practices, especially in Japan, where cord blood transplantation (CBT) is prevalent, is crucial. A total of 40,444 allogeneic HSCT cases in Japan between 2011 and 2021 were examined using an interrupted time series analysis to assess the impact of COVID-19 on CBT utilization. Following the SARS-CoV-2 pandemic, CBT cases demonstrated a significant increase (11.06 [95% confidence interval (CI): 1.87 to 20.25] cases per month), whereas bone marrow transplantation cases decreased, by 10.74 cases per month (95% CI, -19.84 to -1.63 cases per month). Total HSCT cases remained stable with a level change of 5.47 cases per month (95% CI, -10.07 to 21.01 cases per month) and a trend change of -1.11 cases per month (95% CI, -2.22 to 0.004 cases per month). The interrupted time series analysis showed significantly increased CBT cases in Japan, highlighting its crucial role as an alternative transplant source during the pandemic. CBT offset the impact of the decrease in bone marrow transplantation and contributed to the maintenance of HSCT activity in Japan during the unprecedented crisis.

查看原文本刊更多论文

SARS-CoV-2大流行对日本脐带血移植的影响：来自中断时间序列分析的见解

SARS-CoV-2大流行扰乱了全球卫生保健系统，特别是影响了造血干细胞移植（HSCT）活动。了解SARS-CoV-2大流行对移植实践的影响至关重要，特别是在脐带血移植（CBT）盛行的日本。2011年至2021年期间，日本共有40,444例同种异体造血干细胞移植病例，采用中断时间序列分析来评估COVID-19对CBT使用的影响。在SARS-CoV-2大流行之后，CBT病例显着增加（每月11.06例[95%置信区间（CI）： 1.87至20.25]例），而骨髓移植病例减少，每月10.74例（95% CI, -19.84至-1.63例）。总HSCT病例保持稳定，每月5.47例（95% CI, -10.07至21.01例/月），趋势变化为-1.11例/月（95% CI, -2.22至0.004例/月）。中断的时间序列分析显示，日本的CBT病例显着增加，突出了其作为大流行期间替代移植来源的关键作用。CBT抵消了骨髓移植减少的影响，并有助于维持日本在前所未有的危机期间的造血干细胞移植活动。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone Marrow Transplantation 医学-免疫学

CiteScore

8.40

自引率

8.30%

发文量

337

审稿时长

6 months

期刊介绍： Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation. The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.